GSK, Pfizer Announce Combined HIV/AIDS Drug Business
April 16, 2009
Pharmaceutical companies GlaxoSmithKline and Pfizer have announced that they will combine their HIV/AIDS drug businesses into a new, single company, the Wall Street Journal reports. Under the deal, GSK initially will hold 85% of the joint venture, while Pfizer will hold 15%, the Journal reports (Whalen/Cimilluca, Wall Street Journal, 4/16). The new company will hold a 19% share of the global HIV market and include 11 products already on the market, Reuters reports. In addition, the new company will include a pipeline of six new drugs, four of which are in mid-stage Phase II development (Hirschler, Reuters, 4/16).
According to UNAIDS data, an estimated 33 million people were living with HIV in 2008, of whom about four million were taking HIV/AIDS medications. In 2008, the market for branded HIV medications was worth about $13 billion (Bloomberg, 4/16).
Global Business Coalition, PEPFAR to Launch $5.4 Million Program Providing Home-Based HIV, TB, Malaria Services
This article was provided by Henry J. Kaiser Family Foundation. It is a part of the publication Kaiser Daily HIV/AIDS Report. Visit the Kaiser Family Foundation's website to find out more about their activities, publications and services.